DV
Dividend Vision

PCRX — Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX)

Total return is 227.6% over the past 15.5 years, 452.5 points behind SPY at 680.1%. Its deepest 1-year drawdown was 29.6%.

PCRX is a single-stock equity position in Pacira BioSciences, a pharmaceutical company focused on regional anesthesia and pain management solutions. As an individual equity holding rather than a diversified fund, it does not have a defined distribution frequency or yield profile typical of dividend ETFs, and carries the concentrated risk associated with a single company investment. This holding appeals primarily to investors seeking direct exposure to Pacira's business performance rather than those pursuing diversified dividend income strategies.

PCRX key facts

Asset type
Stock
Asset class
Equity
Inception date
02/03/2011
Distribution frequency
None
Last close
$23.00
Market cap
$916,823,424
Average volume
645100.0
Beta
0.268
Payout ratio
0.0
P/E ratio
65.7143
Forward P/E
8.881
EPS
$0.35